Towards COVID-19 Prophylaxis: An AIDS Preclinical Research Perspective.

Cancer studies and therapeutics Pub Date : 2020-07-01
Michele Di Mascio
{"title":"Towards COVID-19 Prophylaxis: An AIDS Preclinical Research Perspective.","authors":"Michele Di Mascio","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The success of an antiviral drug depends on its potency to neutralize the virus in vitro and its ability after administration in vivo to reach the anatomic compartments that fuel viral dissemination in the body. For instance, remdesivir, a potent SARS-CoV-2 antiviral drug based on studies in vitro, if administered orally would be poorly effective because low drug levels would reach the lungs due to its high first pass destruction in the liver. This is the reason remdesivir can only be administered intravenously, a requirement that clearly limits its use as a prophylactic agent for COVID-19, although novel formulations for its easier administration are under development. Whether an antiviral prophylaxis could further control or even stop the COVID-19 epidemic in synergy with other non-pharmacological based mitigation strategies is today unknown. Since the mid-1960s, pharmacologists have investigated the use of lipid-based nanoparticles for efficient delivery of antivirals to tissues, for example by transforming the route of administration from intravenous to oral, subcutaneous or aerosol administrations. These novel encapsulation strategies have also the potential to maintain high levels of the antiviral drugs in tissues, with reduced dose frequency compared to the non-encapsulated drug. Several lipid-based nanoparticles are today approved by the US Food and Drug Administration or being tested in clinical studies with favorable toxicity profiles. Nonhuman primate models of coronavirus infection offer unique platforms to accelerate the search for SARS-CoV-2 antiviral prophylaxis. Paradigms, to corroborate this claim, are borrowed from nonhuman primate research studies, some of which had a profound impact on global public health in the specific setting of the AIDS pandemic. Sharing information from nonhuman primate research programs, invoking principles of scientific transparency and bioethics similar to those universally agreed for human studies, would also likely significantly help our collective fight (as the human species) against this public health emergency.</p>","PeriodicalId":72517,"journal":{"name":"Cancer studies and therapeutics","volume":"5 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7472709/pdf/nihms-1623304.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer studies and therapeutics","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The success of an antiviral drug depends on its potency to neutralize the virus in vitro and its ability after administration in vivo to reach the anatomic compartments that fuel viral dissemination in the body. For instance, remdesivir, a potent SARS-CoV-2 antiviral drug based on studies in vitro, if administered orally would be poorly effective because low drug levels would reach the lungs due to its high first pass destruction in the liver. This is the reason remdesivir can only be administered intravenously, a requirement that clearly limits its use as a prophylactic agent for COVID-19, although novel formulations for its easier administration are under development. Whether an antiviral prophylaxis could further control or even stop the COVID-19 epidemic in synergy with other non-pharmacological based mitigation strategies is today unknown. Since the mid-1960s, pharmacologists have investigated the use of lipid-based nanoparticles for efficient delivery of antivirals to tissues, for example by transforming the route of administration from intravenous to oral, subcutaneous or aerosol administrations. These novel encapsulation strategies have also the potential to maintain high levels of the antiviral drugs in tissues, with reduced dose frequency compared to the non-encapsulated drug. Several lipid-based nanoparticles are today approved by the US Food and Drug Administration or being tested in clinical studies with favorable toxicity profiles. Nonhuman primate models of coronavirus infection offer unique platforms to accelerate the search for SARS-CoV-2 antiviral prophylaxis. Paradigms, to corroborate this claim, are borrowed from nonhuman primate research studies, some of which had a profound impact on global public health in the specific setting of the AIDS pandemic. Sharing information from nonhuman primate research programs, invoking principles of scientific transparency and bioethics similar to those universally agreed for human studies, would also likely significantly help our collective fight (as the human species) against this public health emergency.

面向COVID-19预防:艾滋病临床前研究视角
抗病毒药物的成功取决于其在体外中和病毒的效力,以及在体内给药后到达促进病毒在体内传播的解剖腔室的能力。例如,瑞德西韦(remdesivir)是一种基于体外研究的强效SARS-CoV-2抗病毒药物,如果口服,效果会很差,因为低水平的药物会到达肺部,因为它在肝脏中的首次破坏程度很高。这就是瑞德西韦只能静脉注射的原因,这一要求显然限制了它作为COVID-19预防药物的使用,尽管正在开发更容易给药的新配方。目前尚不清楚抗病毒预防是否能与其他非药物缓解策略协同作用,进一步控制甚至阻止COVID-19的流行。自20世纪60年代中期以来,药理学家一直在研究利用脂质纳米颗粒将抗病毒药物有效地输送到组织中,例如将给药途径从静脉注射转变为口服、皮下或气雾剂给药。这些新的包封策略也有可能在组织中保持高水平的抗病毒药物,与非包封药物相比,其剂量频率降低。目前,美国食品和药物管理局批准了几种基于脂质的纳米颗粒,或正在临床研究中进行测试,具有良好的毒性。冠状病毒感染的非人灵长类动物模型为加速寻找SARS-CoV-2抗病毒预防方法提供了独特的平台。为了证实这一说法,从非人类灵长类动物研究中借鉴了一些范例,其中一些范例在艾滋病大流行的特定背景下对全球公共卫生产生了深远影响。分享来自非人类灵长类动物研究项目的信息,援引类似于人类研究普遍认可的科学透明度和生物伦理原则,也可能极大地帮助我们(作为人类物种)共同对抗这场公共卫生紧急事件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信